Modified Immune Cells Target Cancer’s Metabolic Signature
Stanford researchers engineered natural killer (NK) and cytotoxic T cells to overexpress metabolite‑sensing G protein‑coupled receptors, most notably GPR183, enabling the cells to home toward tumor‑derived metabolic cues. In mouse models of triple‑negative breast and ovarian cancer, GPR183‑enhanced NK‑92 cells and CAR‑NK cells markedly slowed tumor growth, and GPR183‑modified T cells achieved complete tumor regression in 7 of 10 immunocompetent mice versus 3 of 10 controls. The study identified eight receptors that improve infiltration, highlighting metabolism‑driven targeting as a novel immunotherapy strategy.
Polysaccharide Microneedles and 3D Printing Explored for Cancer Immunotherapy Applications
Researchers reviewed polysaccharide‑based microneedles as a platform for cancer immunotherapy, emphasizing how additive manufacturing—particularly high‑resolution 3D printing—can create customizable transdermal delivery arrays. Natural polymers such as hyaluronic acid, chitosan and alginate provide biocompatibility and enable dissolvable or hydrogel‑based needles with...
Pig Liver Xenotransplant Shows Promise, but More Work Remains
Genetically modified pig livers have entered early clinical testing, with a Chinese patient surviving 171 days after transplantation. Researchers in China are exploring pig livers as auxiliary support, while a University of Pennsylvania team is evaluating extracorporeal pig livers as...
Last Call for Microbiome Start-Ups and Research Abstracts for Probiota Americas
NutraIngredients is inviting consumer‑facing, science‑driven startups and researchers to submit entries for its Probiota Pioneers and Scientific Frontiers tracks, with winners presenting at Probiota Americas in Vancouver from June 8‑10, 2026. Startups must be Americas‑based, under 20 employees, founded within ten years...
Biogen, with $5.6B Apellis Buy, Builds Out Immunology Offerings
Biogen announced a $5.6 billion cash acquisition of Apellis Pharmaceuticals, paying $41 per share—a 140% premium—and issuing contingent value rights worth up to $4 per share. The deal brings two recently launched products, the eye‑disease therapy Syfovre and the rare‑kidney drug...
Short-Acting Psychedelic DMT Shows Promise as a Rapid Treatment for Major Depressive Disorder
A phase IIa trial published in Nature Medicine found that a single intravenous dose of dimethyltryptamine (DMT), paired with structured psychotherapy, produced a rapid and sustained reduction in major depressive disorder symptoms. Participants receiving 21.5 mg of DMT showed an average...
Unlocking Designer Roots for Future Cereal Crops
Researchers at the University of Queensland and Australian National University identified the CEPR1 signaling gene as a conserved regulator of root architecture across barley, rice, maize and Arabidopsis. Knocking out CEPR1 creates steeper, narrower roots that improve water and nutrient...
Henan Lvyuan Pharmaceutical Co. Ltd. - 722497 - 03/26/2026
The FDA issued a warning letter to Henan Lvyuan Pharmaceutical after a September 2025 inspection uncovered multiple Current Good Manufacturing Practice (CGMP) violations. Inspectors cited severe facility maintenance issues, including corrosion and water leaks that could compromise API potency and...
Microbiological Testing & Consulting, LLC - 720374 - 03/16/2026
The FDA issued Warning Letter 320‑26‑53 to Microbiological Testing & Consulting, LLC after a September 2025 inspection uncovered multiple Current Good Manufacturing Practice (CGMP) violations. The firm failed to maintain adequate laboratory controls, documentation, media qualification, and a functional quality‑control unit,...
Medtronic to Study Renal Denervation Combined with PCI
Medtronic announced the EMBRACE trial, a randomized study enrolling 1,000 patients to evaluate its Symplicity Spyral renal denervation system performed concurrently with percutaneous coronary intervention (PCI) in individuals with uncontrolled hypertension and multivessel disease. The company also released pooled data...
FDA Identifies Cases of Serious Liver Injury in Patients Taking Tavneos (Avacopan) for Severe Active Anti-Neutrophil Cytoplasmic Autoantibody (ANCA)-Associated Vasculitis
The FDA issued a drug safety communication warning that Tavneos (avacopan) is linked to 76 post‑marketing cases of drug‑induced liver injury, including eight fatalities. Seven patients developed biopsy‑confirmed vanishing bile duct syndrome, a severe cholestatic condition, with three deaths. Median...
Companies that Have Not Submitted Drug Amount Reports
The FDA has released two public lists identifying registrants that failed to submit required drug amount reports for calendar year 2024. One list covers entities with active drug listings, the other captures those with inactive listings. Registrants must certify or...
October - December 2025 | New Safety Information or Potential Signals of Serious Risks Identified by the FDA Adverse Event...
The FDA’s Adverse Event Monitoring System (AEMS) released a slate of new safety signals for a range of products covering October‑December 2025. Alerts include heightened hypersensitivity reactions for certain lots of Alyglo, hypogammaglobulinemia linked to multiple bispecific T‑cell engager therapies,...
Longer-Term Real-World Data Needed to Compare Leqembi and Kisunla Opposing Treatment Strategies for Alzheimer’s
Eisai/Biogen’s Leqembi and Eli Lilly’s Kisunla are the only FDA‑approved disease‑modifying Alzheimer’s therapies, but they follow opposite treatment models—continuous dosing versus a finite course after amyloid clearance. Four‑year data presented at AD/PD 2026 showed Leqembi delayed disease progression by roughly 9.8 months, with...
Reversing Extinction
Historian Sadiah Qureshi’s Aeon essay examines the rise of de‑extinction technologies, from cloning the last Pyrenean ibex to gene‑editing wolves to resemble extinct dire wolves. She argues that preserving genetic material in labs creates a liminal state where species are...
Merck Strikes Deal with Antibody Discovery Startup
Merck has signed a research collaboration with AI‑driven antibody startup Infinimmune, potentially providing up to $838 million in payments tied to clinical milestones. Infinimmune’s platform scans human immune cells to uncover novel targets such as IL‑22 and IL‑13 for autoimmune indications....
MRNA Is Poised to Rise Beyond Infectious Diseases, if It’s Not Derailed by R&D Cuts
mRNA technology, once celebrated for COVID‑19 vaccines, now faces heightened political and regulatory scrutiny, including the cancellation of roughly $500 million in BARDA contracts. A new JAMA Network Open study shows NIH has invested $1.65 billion in 178 mRNA grants since 1997,...
Novo Nordisk Launches Subscription Program for Wegovy Drugs
Novo Nordisk introduced a subscription service for its obesity treatment Wegovy, allowing cash‑pay patients to lock in three‑month, six‑month or twelve‑month supplies. The model promises lower out‑of‑pocket costs compared with traditional pay‑per‑dose purchases. By bundling shots and oral pills, Novo...
UCB Brings First Therapy for Rare Disease TK2d to EU
UCB’s Kygevi, a combination of doxecitine and doxribtimine, received its first EU approval for treating thymidine kinase 2 deficiency (TK2d) under exceptional circumstances. The drug, aimed at patients whose disease began before age 12, cut mortality risk by 95% compared with...
PepGen’s Muscle Disease Program Posts Poor Mid-Stage Results as One Patient's Data Get Markedly Worse
PepGen reported that its Phase 2 trial of an oligonucleotide therapy for a rare genetic nerve‑muscle disorder failed to meet its primary efficacy endpoints. The data showed no statistically significant improvement in muscle strength across the cohort, and one participant experienced...
O-GlcNAcylation of UGDH: New Immunometabolic Insights
Researchers led by Wu, Lei and Wang have shown that O‑GlcNAcylation of the metabolic enzyme UGDH reshapes its activity, steering UDP‑glucuronic acid production and downstream glycan synthesis. This post‑translational modification links nutrient‑sensing pathways to immune cell adhesion, migration, and signaling,...
Eli Lilly to Buy Centessa for $6.3B to Get Sleep Disorder Drug
Eli Lilly announced a $6.3 billion acquisition of Centessa Pharmaceuticals, marking its largest deal in years. The purchase secures Centessa’s orexin‑based insomnia candidate and a pipeline of early‑stage neurological programs. Lilly is channeling cash generated by its GLP‑1 blockbuster drugs into the...
First Clinical Trial of tRNA Therapy Will Start Soon
Alltrna, a biotech startup focused on transfer RNA (tRNA) therapeutics, has secured regulatory clearance to launch its first human clinical trial. The trial will evaluate a novel tRNA‑based drug designed to correct protein synthesis errors that underlie a range of...
Enveda's First Clinical Readout Shows Strong Eczema Results
Enveda Biosciences released its first clinical readout for an investigational atopic dermatitis therapy, showing efficacy comparable to AbbVie's Dupixent. The Phase 1 trial met its primary endpoints, demonstrating significant skin clearance and a safety profile similar to existing biologics. The...
Semarion Raises $3.8M to Scale Cell Assay Technology
Semarion, a Cambridge spin‑out, secured $3.8 million (≈£2.9 million) in a Series A round led by Parkwalk to scale its SemaCyte cell‑based screening platform. The funding follows a $2.89 million seed round in 2022 and will be used to expand manufacturing, field support,...
Alterity Receives Positive FDA Feedback on ATH434 Phase 3 Program
Alterity Therapeutics received positive written feedback from the U.S. Food and Drug Administration after a Type C meeting on its planned Phase 3 program for ATH434 in Multiple System Atrophy. The agency endorsed the company’s clinical pharmacology and non‑clinical development strategy and...
AZ Considers Filings for Long-Acting Strensiq Follow-Up
AstraZeneca’s Alexion unit intends to file a new long‑acting enzyme replacement therapy, efzimfotase alfa, as a successor to its Strensiq (asfotase alfa) for hypophosphatasia (HPP). Phase 3 data showed the drug met primary endpoints in pediatric patients but failed to achieve...
Homoharringtonine Extends Lifespan, Fights Obesity in Mice
Researchers reported that homoharringtonine (HHT), a plant‑derived alkaloid already approved for certain blood cancers, acts as a potent senolytic in mice. The compound selectively eliminated senescent cells across adipose, liver and muscle, leading to lower inflammation, improved glucose tolerance and...
Structural and Genetic Analysis of Neutralizing Antibodies Reveals Mechanisms of GII.4 Norovirus Antigenic Evolution
Researchers solved the atomic structures of two neutralizing monoclonal antibodies against the pandemic GII.4 norovirus, targeting the principal antigenic sites A and G. The spatial positioning of site G was shown to shape neutralizing responses, while coordinated substitutions within these...
Blackstone Closes $6.3bn Life Sciences Fund
Blackstone announced the closing of its newest life sciences fund at $6.3 billion, topping the original target. The vehicle will back biotech, pharmaceutical and medical‑technology companies from seed to growth stages. Investor enthusiasm for health‑tech has surged since the pandemic, allowing...
UBriGene and Cellinfinity BIO Collaborate to Accelerate in Vivo CAR-T Therapies
uBriGene Biosciences has entered a strategic partnership with Cellinfinity BIO to accelerate the development of in‑vivo CAR‑T therapies for both solid tumors and hematologic cancers. The collaboration will apply uBriGene’s LVV Turbo platform, which delivers up to 80% purification recovery...
UBriGene and Cellinfinity BIO Collaborate to Accelerate in Vivo CAR-T Therapies
uBriGene Biosciences has entered a strategic partnership with Cellinfinity BIO to fast‑track in‑vivo CAR‑T programs for both solid and hematologic cancers. The deal leverages uBriGene’s LVV Turbo platform, which delivers GMP‑grade lentiviral vectors with up to 80% purification recovery and...
ACC 2026: Lorundrostat Lowers BP but Raises Hyperkalemia Risk
At the 2026 ACC Scientific Session, Brazilian investigators presented a meta‑analysis of three placebo‑controlled trials (1,060 patients) evaluating lorundrostat in uncontrolled hypertension. Lorundrostat 50 mg reduced systolic blood pressure by 9.08 mm Hg and diastolic by 3.48 mm Hg, while the 100 mg dose achieved an...
Blackstone Closes Record $6.3bn Life Sciences Fund
Blackstone announced that its sixth life sciences fund, BXLS VI, closed at $6.3 billion, making it the largest private fund ever raised for the sector. The fund was oversubscribed and is about 40% larger than the $4.6 billion fifth fund closed in 2020,...
Merck Reports P-III (CORALreef AddOn) Trial Data on Enlicitide Decanoate in Hypercholesterolemia
Merck presented Phase III CORALreef AddOn trial results for enlicitide decanoate, an oral PCSK9 inhibitor, in hypercholesterolemic adults on statins. At eight weeks, the drug lowered LDL‑C by 64.6%, outperforming bempedoic acid, ezetimibe and their combination. It also achieved 54.6%...
STAT+: Over-the-Top Psychedelic Promos Could Undermine the Field’s Drug Development Efforts
Psychedelic biotech firms Helus Pharma and AtaiBeckley have hired marketing agencies to produce YouTube videos that tout exaggerated efficacy claims and alleged FDA fast‑track status for their investigational drugs. The ads, labeled only as “informational,” suggest near‑perfect Phase 2 results and...
Standing Ovation Raises €30M to Scale Precision Fermentation Dairy Proteins Globally
Standing Ovation, a French precision‑fermentation startup, closed a €30 million Series B round (≈$32.5 million) led by the France 2030‑backed Ecotechnologies 2 fund and Crédit Mutuel Innovation, with participation from Danone Ventures, Bel Group and other investors. The financing includes €25 million in equity (≈$27 million) and...
Teva Advances Biosimilars Portfolio with Ponlimsi (Denosumab) FDA Approval and Dual Omalizumab Filing Acceptance
Teva Pharmaceutical received U.S. FDA approval for Ponlimsi, a biosimilar to Amgen’s Prolia (denosumab), covering all approved indications. The approval was granted after extensive analytical and clinical studies demonstrated comparable efficacy, safety, and immunogenicity to the reference product. In parallel,...
Vertically Stacked Paper‐Based Microarray Device for High‐Throughput SERS Detection of Two Cancer Biomarkers
Researchers have unveiled a vertically stacked paper‑based microarray device (µAPAD) that integrates the full immunoassay workflow for high‑throughput SERS detection of cancer biomarkers. The 16‑layer wax‑patterned platform ensures uniform nanotag distribution, cutting signal variation from 36.6% to 6.69% and enabling...
Extrahepatic Gene Editing In Vivo Using Organic Solvent‐Free Lipid Nanoparticles
Researchers have unveiled a fully water‑based lipid nanoparticle (LNP) platform that eliminates cholesterol and PEG, using poly(2‑methyl‑2‑oxazoline) as a stealth polymer. The solvent‑free formulation enables efficient delivery of CRISPR‑Cas9 components, achieving robust gene editing in primary human immune cells and...
Bioinspired Anti‐VEGF Peptide Nanoparticle with Immune Regulating and Corneal Epithelium Penetration Capability for Corneal Neovascularization Therapy
Researchers have engineered a bioinspired nanoparticle that co‑assembles an anti‑VEGF peptide with copper ions, adds a ROS‑scavenging moiety and a cell‑penetrating peptide, and achieves deep corneal delivery. The formulation extends ocular residence to roughly 70 minutes and reaches 300 µm in a...
Integrated Transcriptomics–Metabolomics Analysis Reveals Biomarkers and Metabolic Dysregulation Characteristics of Parenteral Nutrition–Associated Liver Disease
A mouse model of parenteral nutrition‑associated liver disease (PNALD) was analyzed using combined RNA‑sequencing and untargeted metabolomics. Integrated machine‑learning pipelines (LASSO and SVM‑RFE) pinpointed five gene biomarkers (Itgam, Clec4d, Orm2, Lcn2, Cd14) and three metabolites (6‑n‑octylaminouracil, 6β‑hydroxy‑hydromorphone, α‑teresantalic acid). These...
Common Ancestry Limits Protein Sequence Exploration, Computational Study Shows
Researchers from OIST, ISTA, Vienna and CAB published a computational study in PNAS showing that common ancestry, rather than selection or epistasis, is the primary constraint on protein sequence diversification. By estimating the effective dimensionality of protein families and simulating...
Imunon Inc (IMNN) Q4 2025 Earnings Call Transcript
Imunon reported Q3 2025 results, highlighting $5.3 million cash and a runway extending to mid‑Q1 2026 after a $4.5 million equity raise. Operating expenses fell 31% year‑over‑year, reducing monthly burn to $1.25‑$1.5 million. The pivotal OVATION 3 phase III ovarian‑cancer trial enrolled nine patients, surpassing internal targets,...
Tevogen Bio Holdings Inc (TVGN) Q4 2025 Earnings Call Transcript
VistaGen Therapeutics reported completing the randomized portion of its PALISADE III Phase 3 trial and using the data to implement operational and statistical refinements for the ongoing PALISADE IV study. The company is leveraging third‑party AI and machine learning to...
Tvardi Therapeutics Inc (TVRD) Q4 2025 Earnings Call Transcript
Teva reported Q4 2025 revenue of $4.5 billion, up 3% year‑over‑year, with adjusted EBITDA rising 6% and non‑GAAP EPS of $0.78, a 14% increase. The innovative portfolio contributed over $800 million, driven by AUSTEDO’s $618 million U.S. sales (+38%) and solid gains from...
A Longitudinal DNA Methylation Atlas and Its Link to Brain Structure and Mental Health
Researchers built a longitudinal DNA‑methylation atlas using the IMAGEN cohort of 506 adolescents, identifying 18 coordinated DNAm clusters that persist from age 14 to 19. The cluster architecture was validated in two older‑adult datasets (PPMI and ADNI), demonstrating lifespan stability....
Omeros Corp (OMER) Q4 2025 Earnings Call Transcript
Omeros Corp reported a Q3 2025 net loss of $30.9 million, but secured a transformative agreement with Novo Nordisk that could deliver up to $2.1 billion in upfront and milestone payments. The $240 million upfront cash will retire most short‑term debt and fund more...
Kairos Pharma Ltd (KAPA) Q4 2025 Earnings Call Transcript
Karyopharm Therapeutics posted Q4 2025 revenue of $34.1 million, an 11.8% year‑over‑year increase, while total 2025 revenue reached $146.1 million. Operating efficiency improved, with R&D and SG&A expenses down 17% and 16% respectively, yet the company recorded a GAAP net loss of...
Galectin Therapeutics Inc (GALT) Q4 2025 Earnings Call Transcript
Altimmune reported a strengthened cash position of roughly $340 million, extending its runway through 2028 to fund a pivotal Phase III NASH trial. The company disclosed that the trial will enroll about 1,800 patients globally, testing 1.8 mg and 2.4 mg doses of its...
